GW Pharmaceuticals PLC GWPH Fundamentals and Key Ratios

GW Pharmaceuticals Plc (GWPH) Fundamentals


GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

SHARE INFORMATION
Market Cap	$ 6,907,019,192
Shares Outstanding	31,544,662
Float	15,576,984
Percent Float	49.38%
Short Interest	693,731.00
Short Percent Float	2.2%
Short Interest Ratio	1.15
Short Interest Date	2021-04-15
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 527,205,000
Latest Fiscal EPS	$ -1.68
Latest Fiscal Date	2020-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	562
Institutional Holdings Date	2021-04-30
Institutional Bought Previous 3 Months	1,472,353
Institutional Holdings Percent	142.9%
Institutional Sold Previous 3 Months	20,517,152
Insider Holdings Date	2021-04-30
Insider Bought Previous 3 Months	1,658,370
Insider Holdings Percent	4.2
Insider Sold Previous 3 Months	1,595,724
Insider Shares Owned	15,967,678

TRADING INFO
52 Week High	$ 0.00
52 Week Low	$ 0.00
52 Week High Change	$ 0.00
21 Day Moving Average	$ 0.00
21 Day Extended Moving Average	$ 218.96
50 Day Moving Average	$ 0.00
50 Day Extended Moving Average	$ 218.96
200 Day Moving Average	$ 0.00
200 Day Extended Moving Average	$ 217.354
10 Day Average Volume	-
20 Day Average Volume	-
30 Day Average Volume	-
50 Day Average Volume	-
Alpha	0.006923
Beta	1.6867
Standard Deviation	0.187175
R2	0.215926
7 Day Price Change	$ 0.00
7 Day Percent Change	0.0%
21 Day Price Change	$ 0.00
21 Day Percent Change	0.0%
30 Day Price Change	$ 0.00
30 Day Percent Change	0.0%
Month to Date Price Change	$ 0.00
Month to Date Percent Change	0.0%
Quarter to Date Price Change	$ 0.00
Quarter to Date Percent Change	0.0%
180 Day Price Change	$ 0.00
180 Day Percent Change	0.0%
200 Day Price Change	$ 0.00
200 Day Percent Change	0.0%
Year to Date Price Change	$ 0.00
Year to Date Percent Change	0.0%

PROFITABILITY
EBIT Margin	-12.4%
EBITDA Margin	-9.9%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	-12.5%
Gross Margin	93.1%
Profit Margin TOT	-12.5%

INCOME STATEMENTS
Revenue	$ 559,038,000
Revenue Per Share	$ 17.7221
Revenue (3 Years)	$ 238.53
Revenue (5 Years)	$ 97.94

FINANCIAL STRENGTH
Price to Tangible Book	9.50
Total Debt To Equity	0.10
Int Coverage	-61.80
Current Ratio	4.50
Leverage Ratio	1.20
Quick Ratio	3.40
Long Term Debt To Capital	0.05

VALUATION MEASURES
PE Ratio	-107.30
Enterprise Value	$ 6,398,042,136
Price to Sales	12.3552
Price to Free Cash	-150.00
PE High Last 5 Years	-18.10
Price To Book	9.40
Price To Cash Flow	19.00
PE Low Last 5 Years	-188.80
Price to Tangible Book	9.50

MANAGEMENT EFFECTIVENESS
Receivables Turnover	8.00
Invoice Turnover	0.30
Assets Turnover	0.60
Return Assets	-7.58
Return on Equity	-9.33
Return on Capital	-9.05

PROFILE INFO
Issue Type	CS
SEC Type	DR
Auditor	Deloitte & Touche LLP
CEO	Justin David Gover
Emplyoees	1161
Last Audit	UQ
CIK	0001351288
Industry	Drug Manufacturers
Sector	Healthcare
NAICS	-

CONTACT INFO
Address	Sovereign House, Chivers Way Vision Park, Histon Cambridge, CB24 9BZ
Website	http://www.gwpharm.com
Facsimile	+44 1223235667
Telephone	+44 1223266800
Email	sschultz@gwpharm.com

Boards:

Quotes:

GWPH